Related Experiment Videos
CytoGam infusions at home
1Lincolnland Home Care of Sarah Bush Lincoln, Mahoon, IL.
Insights
CytoGam, a hyperimmune globulin, prevents cytomegalovirus (CMV) infections in organ transplant recipients. Clinical studies show it significantly reduces CMV development, offering hope for immunocompromised patients.
Area of Science:
- Immunology
- Transplantation Medicine
- Virology
Background:
- Cytomegalovirus (CMV) poses a significant risk to organ transplant recipients, particularly when donors are seropositive and recipients are seronegative.
- Hyperimmune globulin therapies are crucial for preventing opportunistic infections in immunocompromised individuals.
Purpose of the Study:
- To evaluate the prophylactic efficacy of CytoGam in preventing cytomegalovirus (CMV) infection in seronegative organ transplant recipients receiving organs from CMV-seropositive donors.
- To assess the role of CytoGam in reducing CMV incidence in patients with human immunodeficiency virus (HIV).
Main Methods:
- CytoGam, a hyperimmune globulin derived from pooled human plasma rich in CMV antibodies (immunoglobulin G, A, and M), was administered prophylactically.
- Clinical studies and trial testing were conducted to assess the impact of CytoGam treatment on CMV development.
Main Results:
- Clinical studies demonstrated a marked decrease in the incidence of cytomegalovirus (CMV) in transplant recipients treated with CytoGam.
- Trial testing indicated potential for CytoGam in decreasing CMV instances in patients with human immunodeficiency virus (HIV).
Conclusions:
- CytoGam is an effective prophylactic agent against cytomegalovirus (CMV) in high-risk organ transplant recipients.
- The established efficacy and potential for long-term use necessitate home intravenous care for CytoGam therapy.
Abstract:
CytoGam is a hyperimmune globulin created specifically for prophylactic use when a cytomegalovirus seronegative patient receives an organ from a seropositive donor. CytoGam is derived from human pooled plasma rich with cytomegalovirus antibodies, immunoglobulin G, and trace amounts of immunoglobulin A and immunoglobulin M. Clinical studies show a marked decrease in the development of cytomegalovirus when transplant recipients are treated with CytoGam. CytoGam also has undergone trial testing for use in decreasing the instance of cytomegalovirus in patients with human immune deficiency virus (HIV). CytoGam therapy may continue for several months, making home intravenous care essential.